QN-302

N/A

Report date: 2025/06/06 11:51:07
NMEFirst In Class

Base Information

Drug NameQN-302
Drug Alias NameQN-302SOP-1812
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionATP-dependent DNA/RNA helicase DHX36 inhibitors
TargetsATP-dependent DNA/RNA helicase DHX36
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A